Patient and transplantation characteristics
| . | GVHD prophylaxis . | |
|---|---|---|
| CSP . | CSP plus MP . | |
| No. of patients | 60 | 62 |
| Gender (M/F), no. of patients | 39/21 | 39/23 |
| Age (y), range (median) | 1-57 (36) | 12-59 (39) |
| Diagnoses, no. of patients* | ||
| Acute leukemia | 24 | 22 |
| CML | 2 | 2 |
| Lymphoma | 21 | 20 |
| MDS | 11 | 15 |
| Other | 2 | 3 |
| Conditioning regimens, no. of patients | ||
| TBI plus other agents | 51 | 50 |
| Chemotherapy | 9 | 12 |
| . | GVHD prophylaxis . | |
|---|---|---|
| CSP . | CSP plus MP . | |
| No. of patients | 60 | 62 |
| Gender (M/F), no. of patients | 39/21 | 39/23 |
| Age (y), range (median) | 1-57 (36) | 12-59 (39) |
| Diagnoses, no. of patients* | ||
| Acute leukemia | 24 | 22 |
| CML | 2 | 2 |
| Lymphoma | 21 | 20 |
| MDS | 11 | 15 |
| Other | 2 | 3 |
| Conditioning regimens, no. of patients | ||
| TBI plus other agents | 51 | 50 |
| Chemotherapy | 9 | 12 |
CML = chronic myelogenous leukemia; MDS = myelodysplastic syndrome; TBI = total body irradiation.
Patients were not in remission (resistant disease or relapse) or, with l ymphoid malignancies, were in third or subsequent remission or, with myeloid malignancies, in second or subsequent remission.